Ivanjko, Natalia
Stokovic, Nikola
Pecin, Marko
Vnuk, Drazen
Smajlovic, Ana
Ivkic, Niko
Capak, Hrvoje
Javor, Ana
Vrbanac, Zoran
Maticic, Drazen
Vukicevic, Slobodan http://orcid.org/0000-0003-4076-0285
Funding for this research was provided by:
H2020 Health (779340, 779340, 779340, 779340, 779340, 779340, 779340, 779340, 779340, 779340, 779340)
European Regional Development Fund (KK.01.1.1.01.0008, KK.01.1.1.01.0008, KK.01.1.1.01.0008)
FP7 Health Program (HEALTH‐F4‐2011‐279239, HEALTH‐F4‐2011‐279239, HEALTH‐F4‐2011‐279239, HEALTH‐F4‐2011‐279239, HEALTH‐F4‐2011‐279239)
Article History
Received: 26 September 2023
Accepted: 30 November 2023
First Online: 12 December 2023
Competing interests
: S.V. is a founder of Genera Research and a coordinator of the EU HORIZON 2020 Grant OSTEOproSPINE funding clinical studies of the new drug for bone repair (patent WO2019076484A1).